Semus Wealth Partners LLC Increases Stake in Eli Lilly and Company (NYSE:LLY)

Key Points

• Semus Wealth Partners LLC increased its holdings in Eli Lilly and Company by 10.1% during the first quarter, now owning 3,671 shares valued at approximately $3.03 million.
• Analysts have generally assigned a consensus rating of "Moderate Buy" to Eli Lilly, with a mix of buy and hold ratings and a target price of around $1,012.56.
• The company recently announced a quarterly dividend of $1.50 per share, representing an annualized yield of 0.74%, with a payout ratio of 48.82%.

Semus Wealth Partners LLC grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 10.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 3,671 shares of the company's stock after buying an additional 338 shares during the period. Eli Lilly and Company makes up about 2.1% of Semus Wealth Partners LLC's investment portfolio, making the stock its 12th largest holding. Semus Wealth Partners LLC's holdings in Eli Lilly and Company were worth $3,032,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Geode Capital Management LLC raised its position in Eli Lilly and Company by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock worth $13,389,651,000 after acquiring an additional 291,875 shares during the period. GAMMA Investing LLC boosted its stake in shares of Eli Lilly and Company by 103,831.6% during the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after acquiring an additional 14,852,076 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Eli Lilly and Company by 19.0% during the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock worth $9,747,214,000 after acquiring an additional 2,012,129 shares during the last quarter. Capital Research Global Investors boosted its stake in shares of Eli Lilly and Company by 16.1% during the 4th quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock worth $8,304,811,000 after acquiring an additional 1,493,673 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Eli Lilly and Company by 14.6% during the 4th quarter. Northern Trust Corp now owns 9,448,219 shares of the company's stock worth $7,294,025,000 after acquiring an additional 1,204,337 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 0.3%

Shares of NYSE LLY traded up $2.10 during trading hours on Wednesday, hitting $765.05. 1,985,783 shares of the company traded hands, compared to its average volume of 3,770,230. The stock has a market capitalization of $725.06 billion, a price-to-earnings ratio of 62.23, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company's 50 day moving average price is $773.36 and its 200 day moving average price is $800.41. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the prior year, the company posted $2.58 EPS. The company's revenue was up 45.2% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.78%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Morgan Stanley reiterated an "overweight" rating and set a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $1,012.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.